27 Mar 2022
Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022
Author: admintech | Filed under: Press ReleaseHANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX:1672) today announces that the latest preclinical research results of the company’s two novel anti-cancer drug candidates, ASC61, an oral PD-L1 inhibitor and ASC60, an oral fatty acid synthase…